Chimerix, Inc.

DB:CXF Stock Report

Market Cap: €74.8m

Chimerix Valuation

Is CXF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CXF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CXF (€0.83) is trading below our estimate of fair value (€199.64)

Significantly Below Fair Value: CXF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CXF?

Key metric: As CXF barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CXF. This is calculated by dividing CXF's market cap by their current book value.
What is CXF's PB Ratio?
PB Ratio0.6x
BookUS$135.78m
Market CapUS$79.14m

Price to Book Ratio vs Peers

How does CXF's PB Ratio compare to its peers?

The above table shows the PB ratio for CXF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average12.8x
HPHA Heidelberg Pharma
3.1x-33.0%€111.9m
MDG1 Medigene
0.8x11.0%€16.7m
2INV 2invest
1xn/a€64.4m
VSC 4SC
46xn/a€50.2m
CXF Chimerix
0.6x36.1%€79.1m

Price-To-Book vs Peers: CXF is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (12.8x).

Price to Book Ratio vs Industry

How does CXF's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
CXF 0.6xIndustry Avg. 2.5xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CXF is good value based on its Price-To-Book Ratio (0.6x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is CXF's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CXF PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CXF's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CXF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.82
€6.67
+708.4%
32.6%€10.48€4.76n/a5
Nov ’25€0.83
€6.46
+680.1%
32.6%€10.15€4.61n/a5
Oct ’25€0.78
€6.20
+695.3%
30.9%€9.99€4.54n/a6
Sep ’25€0.83
€6.20
+649.2%
30.9%€9.99€4.54n/a6
Aug ’25€0.77
€6.48
+743.8%
29.7%€10.18€4.63n/a6
Jul ’25€0.80
€6.48
+712.1%
29.7%€10.18€4.63n/a6
Jun ’25€0.88
€6.55
+647.4%
27.5%€10.29€4.68n/a7
May ’25€0.86
€6.55
+664.0%
27.5%€10.29€4.68n/a7
Apr ’25€0.95
€6.46
+583.1%
27.5%€10.15€4.61n/a7
Mar ’25€1.06
€6.46
+506.8%
27.5%€10.15€4.61n/a7
Feb ’25€0.84
€6.91
+725.0%
25.7%€10.36€4.71n/a6
Jan ’25€0.81
€6.91
+749.1%
25.7%€10.36€4.71n/a6
Dec ’24€0.91
€6.91
+658.0%
25.7%€10.36€4.71n/a6
Nov ’24€0.89
€6.74
+661.1%
25.7%€10.12€4.60€0.836
Oct ’24€0.89
€6.74
+655.9%
25.7%€10.12€4.60€0.786
Sep ’24€0.97
€6.74
+595.7%
25.7%€10.12€4.60€0.836
Aug ’24€1.05
€7.02
+569.0%
27.8%€10.08€4.58€0.776
Jul ’24€1.10
€7.02
+538.0%
27.8%€10.08€4.58€0.806
Jun ’24€1.26
€7.09
+461.5%
27.8%€10.17€4.62€0.886
May ’24€1.05
€7.24
+592.6%
29.7%€10.21€4.64€0.865
Apr ’24€1.14
€7.24
+538.0%
29.7%€10.21€4.64€0.955
Mar ’24€1.47
€7.98
+442.5%
26.2%€10.97€5.99€1.065
Feb ’24€1.62
€7.98
+393.1%
26.2%€10.97€5.99€0.845
Jan ’24€1.72
€7.98
+364.0%
26.2%€10.97€5.99€0.815
Dec ’23€2.22
€7.98
+259.2%
26.2%€10.97€5.99€0.915
Nov ’23€1.87
€7.99
+327.1%
26.2%€10.99€6.00€0.895

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Regeneron Pharmaceuticals

US$80.7b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

RGO

US$720.00

7D

1.8%

1Y

-5.2%

Collegium Pharmaceutical

US$983.6m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

0%

1Y

23.9%

Almirall

€1.9b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.70

7D

4.9%

1Y

3.8%